Abstract
Sildenafil citrate (UK-92,480, Viagra®) is a selective inhibitor of phosphodiesterase type 5 (PDE5) and acts on the nitric oxide (NO)/cyclic guanosine monophosphate (cGMP) pathway [1, 2]. UK-92,480 was first synthesised in the Sandwich laboratories of Pfizer Ltd, UK in 1989, and resulted from a discovery programme aimed at developing a selective inhibitor of PDE5. The origins of the project that eventually led to the discovery and development of Viagra date from around the mid 1980s. At this time, scientists working at the Pfizer European Research Centre were interested in potential new approaches to the treatment of several cardiovascular diseases.
Keywords
- Nitric Oxide
- Erectile Dysfunction
- Multiple System Atrophy
- Erectile Function
- Corpus Cavernosum
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, access via your institution.
Buying options
Preview
Unable to display preview. Download preview PDF.
References
Jeremy JY, Ballard SA, Naylor AM, Miller MAW, Angelini GD (1997) Effects of sildenafil, a type-5 cGMP phosphodiesterase inhibitor, and papaverine on cyclic GMP and cyclic AMP levels in the rabbit corpus cavernosum in vitro. Br J Urol 79: 958–963
Boolell M, Allen MJ, Ballard SA, Gepi-Attee S, Muirhead GJ, Naylor AM, Osterloh IH, Gingell C (1996) Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction. Int J Impot Res 8: 47–52
Moncada S, Higgs A (1993) The L-arginine-nitric oxide pathway. N Engl J Med 329: 2002–2012
Hare TM, Colucci WS (1995) Role of nitric oxide in the regulation of myocardial function. Prog Cardiovasc Dis 38: 155–166
Beavo JA (1995) Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. Physiol Rev 75: 725–748
Terrett N, Bell A, Brown D, Ellis P (1996) Sildenafil (Viagra), a potent and selective inhibitor of type 5 cGMP phosphodiesterase with utility for the treatment of male erectile dysfunction. Bioorg Med Chem Lett 6: 1819–1824
Ballard SA, Gingell CJ, Tang K, Turner LA, Price ME, Naylor AM (1998) Effects of sildenafil on the relaxation of human corpus cavernosum tissue in vitro and on the activities of cyclic nucleotide phosphodiesterase isozymes. J Urol 159: 2164–2171
Lue TF (2000) Erectile dysfunction. N Engl J Med 342: 1802–1813
Jackson G, Benjamin N, Jackson N, Allen MJ (1999) Effects of sildenafil citrate on human hemodynamics. Am J Cardiol 83: 13C–20C
Wallis RM, Corbin JD, Francis SH, Ellis P (1999) Tissue distribution of phosphodiesterase families and the effects of sildenafil on tissue cyclic nucleotides, platelet function, and the contractile responses of trabeculae carneae and aortic rings in vitro. Am J Cardiol 83: 3C–12C
Muirhead GJ, Rance DJ, Walker DK, Wastall P (2002) Comparative human pharmacokinetics and metabolism of single-dose oral and intravenous sildenafil. Br J Clin Pharmacol 53 (Suppl 1): 13S–20S
Nichols DJ, Muirhead GJ, Harness JA (2002) Pharmacokinetics of sildenafil citrate after single oral doses in healthy male subjects: absolute bioavailability, food effects and dose proportionality. Br J Clin Pharmacol 53: 5S–12S
Webb DJ, Freestone S, Allen MJ, Muirhead GJ (1999) Sildenafil citrate and blood-pressure-lowering drugs: results of drug interaction studies with an organic nitrate and a calcium antagonist. Am J Cardiol 83: 21C–28C
Boolell M, Gepi-Attee S, Gingell JC, Allen MJ (1996) Sildenafil, a novel effective oral therapy for male erectile dysfunction. Br J Urol 78: 257–261
Rosen RC, Riley A, Wagner G, Osterloh IH, Kirkpatrick J, Mishra A (1997) The International Index of Erectile Function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology 49: 822–830
Montorsi F, McDermott TE, Morgan R, Olsson A, Schultz A, Kirkeby HJ, Osterloh IH (1999) Efficacy and safety of fixed-dose oral sildenafil in the treatment of erectile dysfunction of various etiologies. Urology 53: 1011–1018
Dinsmore WW, Hodges M, Hargreaves C, Osterloh IH, Smith MD, Rosen RC (1999) Sildenafil citrate (VIAGRA) in erectile dysfunction: near normalization in men with broad-spectrum erectile dysfunction compared with age-matched healthy control subjects. Urology 53: 800–805
Kloner RA, Brown M, Prisant LM, Collins M (2000) Efficacy and safety of Viagra (sildenafil citrate) in patients with erectile dysfunction taking concomitant antihypertensive therapy. Am J Hypertens 14: 70–73
Conti CR, Pepine CJ, Sweeney M (1999) Efficacy and safety of sildenafil citrate in the treatment of erectile dysfunction in patients with ischemic heart disease. Am J Cardiol 83: 29C–34C
Olsson AM, Persson CA (2001) Efficacy and safety of sildenafil citrate for the treatment of erectile dysfunction in men with cardiovascular disease. Int J Clin Pract 55: 171–176
Rendell MS, Rajfer J, Wicker PA, Smith MD, for the Sildenafil Diabetes Study Group (1999) Sildenafil for treatment of erectile dysfunction in men with diabetes. JAMA 281: 421–426
Giuliano F, Hultling C, El Masry WS, Smith MD, Osterloh IH, Orr M, Maytom M (1999) Randomized trial of sildenafil for the treatment of erectile dysfunction in spinal cord injury. Ann Neurol 46: 15–21
Derry FA, Dinsmore WW, Fraser M, Gardner BP, Glass CA, Maytom MC, Smith MD (1998) Efficacy and safety of oral sildenafil (VIAGRA) in men with erectile dysfunction caused by spinal cord injury. Neurology 51: 1629–1633
Zippe CD, Kedia AW, Kedia K, Nelson DR, Agarwal A (1998) Treatment of erectile dysfunction after radical prostatectomy with sildenafil citrate (Viagra). Urology 52: 963–966
Lowentritt BH, Scardino PT, Miles BJ, Orejuela FJ, Schatte EC, Slawin KM, Elliott SP, Kim ED (1999) Sildenafil citrate after radical retropubic prostatectomy. J Urol 162: 1614–1617
Wagner G, Montorsi F, Auerbach S, Collins M (2001) Sildenafil citrate (VIAGRA) improves erectile function in elderly patients with erectile dysfunction: a subgroup analysis. J Gerontol A Biol Sci Med Sci 56: M113—M119
Hussain IF, Brady CM, Swinn MJ, Mathias CJ, Fowler CJ (2001) Treatment of erectile dysfunction with sildenafil citrate (Viagra) in parkinsonism due to Parkinson’s disease or multiple system atrophy with observations on orthostatic hypotension. J Neurol Neurosurg Psychiatry 71: 371–374
Fowler C, Miller J, Sharief M (1999) Viagra (sildenafil citrate) for the treatment of erectile dysfunction in men with multiple sclerosis. Ann Neurol 46: 497
Chen J, Mabjeesh NJ, Greenstein A, Nadu A, Matzkin H (2001) Clinical efficacy of sildenafil in patients on chronic dialysis. J Urol 165: 819–821
Rosas SE, Wasserstein A, Kobrin S, Feldman HI (2001) Preliminary observations of sildenafil treatment for erectile dysfunction in dialysis patients. Am J Kidney Dis 37: 134–137
Prieto Castro RM, Anglada Curado FJ, Regueiro Lopez JC, Leva Vallejo ME, Molina Sanchez J, Saceda Lopez JL, Requena Tapia MJ (2001) Treatment with sildenafil citrate in renal transplant patients with erectile dysfunction. BJU Int 88: 241–243
Chait J, Kobashigawa J, Chuang J, Moriguchi J, Kawata N, Laks H (1999) Efficacy and safety of sildenafil citrate (Viagra) in male heart transplant patients. J Heart Lung Transplant 18: 58
Wagoner LE, Giesting RM, Bell BJ, McGuire NC, Abraham WT (1999) Is Viagra (sildenafil) safe and effective in cardiac transplant recipients? Transplantation 67: S102
Webster L, Michelakis E, Davis T, Tsuyuki R, Archer S (2002) Sildenafil is safe and effective treatment for erectile dysfunction in males with NYHA class II-III congestive heart failure. Circulation 106 (Suppl. 2): 11–469
Seidman SN, Roose SP, Menza MA, Shabsigh R, Rosen RC (2001) Treatment of erectile dysfunction in men with depressive symptoms: results of a placebo-controlled trial with sildenafil citrate. Am J Psychiatry 158: 1623–1630
Morales A, Gingell C, Collins M, Wicker PA, Osterloh IH (1998) Clinical safety of oral sildenafil citrate (VIAGRA) in the treatment of erectile dysfunction. Int J Impot Res 10: 69–74
Laties AM, Zrenner E (2002) Viagra® (sildenafil citrate) and ophthalmology. Prog Retin Eye Res 21: 485–506
Corbin JD, Francis SH (2002) Pharmacology of phosphodiesterase-5 inhibitors. Int J Clin Pract 56: 453–459
Padma-Nathan H, Eardley I, Kloner RA, Laties AM, Montorsi F (2002) A 4-year update on the safety of sildenafil citrate (Viagra®). Urology 60 (Suppl. 2B): 67–90
Sadovsky R, Miller T, Moskowitz M, Hackett G (2001) Three-year update of sildenafil citrate (Viagra) efficacy and safety. Int J Clin Pract 55: 115–128
Shakir SAW, Wilton LV, Boshier A, Layton D, Heeley E (2001) Cardiovascular events in users of sildenafil: results from first phase of prescription event monitoring in England. BMJ 322: 651–652
Zusman R, Collins M (1999) Effect of sildenafil on blood pressure in men with erectile dysfunction taking concomitant antihypertensive medications. J Am Coll Cardiol 33: 238A
Zusman RM, Morales A, Glasser DB, Osterloh IH (1999) Overall cardiovascular profile of sildenafil citrate. Am J Cardiol 83: 35C–44C
Goldstein I, Lue TF, Padma-Nathan H, Rosen RC, Steers WD, Wicker PA (1998) Oral sildenafil in the treatment of erectile dysfunction. N Engl J Med 338: 1397–1404
Fagelman E, Fagelman A, Shabsigh R (2001) Efficacy, safety, and use of sildenafil in urologic practice. Urology 57: 1141–1144
Marks LS, Duda C, Dorey FJ, Macairan ML, Santos PB (1999) Treatment of erectile dysfunction with sildenafil. Urology 53: 19–24
Jarow JP, Burnett AL, Geringer AM (1999) Clinical efficacy of sildenafil citrate based on etiology and response to prior treatment. J Urol 162: 722–725
Moreira SG, Brannigan RE, Spitz A, Orejuela FJ, Lipshultz LI, Kim ED (2000) Side-effect profile of sildenafil citrate (Viagra) in clinical practice. Urology 56: 474–476
Moore R, Edwards J, McQuay H (2002) Sildenafil (Viagra) for male erectile dysfunction: a meta-analysis of clinical trial reports. BMC Urol 2: 1–12
Fink HA, Mac Donald R, Rutks IR, Nelson DB, Wilt TJ (2002) Sildenafil for male erectile dysfunction: a systematic review and meta-analysis. Arch Intern Med 162: 1349–1360
Carson CC, Burnett AL, Levine LA, Nehra A (2002) The efficacy of sildenafil citrate (Viagra®) in clinical populations: an update. Urology 60 (Suppl 2B): 12–27
Berman JR, Berman LA, Toler SM, Gill J, Haughie S for the Sildenafil Study Group (2003) Safety and efficacy of sildenafil citrate for the treatment of female sexual arousal disorder: a double-blind, placebo-controlled study. J Urol 170: 2333–2338
Caruso S, Intelisano G, Lupo L, Agnello C (2001) Premenopausal women affected by sexual arousal disorder treated with sildenafil: a double-blind, cross-over, placebo-controlled study. Br J Obs Gynaecol 108: 623–628
Nurnberg H, Hensley P, Lauriello J, Parker L, Keith S (1999) Sildenafil for women patients with antidepressant-induced sexual dysfunction. Psychiatr Sery 50: 1076–1078
Mark A, Shifren J (2003) Medical therapy for female sexual dysfunction. Prim Care Update Ob/Gyns 10: 40–43
Reffelmann T, Kloner RA (2003) Therapeutic potential of phosphodiesterase 5 inhibition fn for cardiovascular disease. Circulation 108: 239–244
Zhang R, Wang Y, Zhang L, Zhang Z, Tsang W, Lu M, Zhang L, Chopp M (2002) Sildenafil (Viagra) induces neurogenesis and promotes functional recovery after stroke in rats. Stroke 33: 2675–2680
Vlachopoulos C, O’Rourke MF, Hirata K (2001) Sildenafil (Viagra®) improves the elastic properties of the aorta. Am J Hypertens 14: 6A
Mahmud A, Hennessy M, Feely J (2001) Effect of sildenafil on blood pressure and arterial wave reflection in treated hypertensive men. J Hum Hypertens 15: 707–713
Lepore JJ, Maroo A, Pereira NL, Ginns LC, Dec GW, Zapol WM, Bloch KD, Semigran MJ (2002) Effect of sildenafil on the acute pulmonary vasodilator response to inhaled nitric oxide in adults with primary pulmonary hypertension. Am J Cardiol 90: 677–680
Watanabe H, Ohashi K, Takeuchi K, Yamashita K, Yokoyama T, Tran QK, Satoh H, Terada H, Ohashi H, Hayashi H (2002) Sildenafil for primary and secondary pulmonary hypertension. Clin Pharmacol Ther 71: 398–402
Abrams D, Schulze-Neick I, Magee A (2000) Sildenafil as a selective pulmonary vasodilator in childhood primary pulmonary hypertension. Heart 82: E4
Carroll WD, Dhillon R (2003) Sildenafil as a treatment for pulmonary hypertension. Arch Dis Child 88: 827–828
Ghofrani HA, Rose F, Schermuly RT, Olschewski H, Wiedemann R, Kreckel A, Weissmann N, Ghofrani S, Enke B, Seeger W, Grimminger F (2003) Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension. J Am Coll Cardiol 42: 158–164
Hirata K, Adji A, Vlachopoulos C, O’Rourke MF (2003) Sildenafil improves left ventricular systolic function in patients with congestive heart failure: the role of wave reflections. J Am Coll Cardiol 41 (Suppl A): 264A
Katz SD (2003) Potential role of type 5 phosphodiesterase inhibition in the treatment of congestive heart failure. Congest Heart Fail 9: 9–15
Lichtenstein JR (2003) Use of sildenafil citrate in Raynaud’s phenomenon: comment on the article by Thompson et al. Arthritis Rheum 48: 282–283
Francis SH, Turko IV, Corbin JD (2001) Cyclic nucleotide phosphodiesterases: relating structure and function. Prog Nucleic Acid Res Mol Bio 65: 1–52
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2004 Springer Basel AG
About this chapter
Cite this chapter
Osterloh, I.H. (2004). The discovery and development of Viagra® (sildenafil citrate). In: Dunzendorfer, U. (eds) Sildenafil. Milestones in Drug Therapy MDT. Birkhäuser, Basel. https://doi.org/10.1007/978-3-0348-7945-3_1
Download citation
DOI: https://doi.org/10.1007/978-3-0348-7945-3_1
Publisher Name: Birkhäuser, Basel
Print ISBN: 978-3-0348-9631-3
Online ISBN: 978-3-0348-7945-3
eBook Packages: Springer Book Archive